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Abstract - Introduction: Lateral epicondylitis is a common musculoskeletal disorder of the upper limb.
Corticosteroid injection has been widely used as a major mode of treatment. However, better understanding of
the pathophysiology of the disease led to a major change in treating the disease, with new options including
platelet-rich plasma (PRP) are currently used.
Objectives/research aim: To systematically evaluate the effect of corticosteroid versus PRP injections for the
treatment of LE.
Hypothesis: PRP injections provide longer-term therapeutic effect and less rate of complications compared to
corticosteroid injection.
Level of evidence: Level 2 evidence (4 included studies are of level 1 evidence, 1 study of level 2 evidence).
Design: Systematic Review (according to PRISMA guidelines).
Methods: Eleven databases used to search for relevant primary studies comparing the effects of corticosteroid
and PRP injections for the treatment of LE. Quality appraisal of studies performed using Cochrane Handbook
for Systematic Reviews of Interventions Version 5.1.0, CASP Randomised Controlled Trial Checklist, and
SIGN Methodology Checklist 2.
Results: 732 papers were identiﬁed. Five randomised controlled trials (250 Patients) met the inclusion criteria.
Clinical ﬁndings: Corticosteroid injections provided rapid symptomatic improvement with maximum effect at
6/8/8 weeks before symptoms recurrence, whereas PRP showed slower ongoing improvements up to 24/52/104
weeks (3 studies). Corticosteroid showedmore rapid symptomatic improvement of symptoms compared to PRP
up to the study end-point of 3months (1 study). Comparable therapeutic effects of corticosteroid and PRPwere
observed at 6 weeks (1 study). Ultrasonographic Findings: (1) Doppler activity decreased more signiﬁcantly in
patients who received corticosteroid compared to PRP. (2) Reduced tendon thickness and more patients with
cortical erosion noted in corticosteroid group whereas increased tendon thickness and less number of patients
with common extensor tendon tears noted in PRP group. (3) Fewer patients reported Probe-induced tenderness
and oedema in the common extensor tendon in both corticosteroid and PRP groups (2 studies).
Conclusion: Corticosteroid injections provide rapid therapeutic effect in the short-term with recurrence of
symptoms afterwards, compared to the relatively slower but longer-term effect of platelet-rich plasma.
Key words: Tennis elbow, Lateral epicondylitis, Epicondylopathy, Epicondylalgia Corticosteroid, Steroid
injections, Platelet-rich plasma, PRP injectionsIntroduction
Tennis elbow or lateral epicondylitis (LE), is one of the
most common and painful musculo-skeletal conditions,
which has a signiﬁcant impact on the healthcare industry
and society in general [1,2]. Lateral epicondylitis is a
common term used to describe a group of symptomsding author: W.O.Ben-Nafa@edu.salford.ac.uk
penAccess article distributed under the terms of the CreativeCom
which permits unrestricted use, distribution, and reproduction iincluding pain and tenderness over the origin of extensor
muscles of the wrist and ﬁngers [3,4]. With a prevalence
rate of more than 1% among the general population, and
with a slight predominance among females [5,6] the disease
mostly affects people aged between 35–50 years, who have
a history of repetitive activities involving the upper limb
[7,8]. While the exact pathophysiology behind the condi-
tion is not yet clear, and despite the presence of
inﬂammatory cells locally, there is a strong argumentmonsAttribution License (http://creativecommons.org/licenses/by/4.0),
n any medium, provided the original work is properly cited.
2 W. Ben-Nafa and W. Munro: SICOT-J 2018, 4, 11that LE can be regarded as a degenerative process caused
by muscle overuse, with subsequent tendinosis, micro-
trauma and tear of the extensor carpi radialis brevis
tendon [9,10].
The relatively large number of options currently
available for the treatment of lateral epicondylitis
[11,12], could be attributed to the scarce evidence
available about the disease aetiology and the lack of
agreement about a deﬁnitive treatment for the condition.
Corticosteroid injection has been considered a major
treatment option for LE [9]. As corticosteroid mainly aims
to reduce inﬂammation, it is apparently questionable
whether it has any possible long-term healing potential
with the disease’s degenerative changes [10]. Besides the
known local and systemic side effects associated with its
use [11,13–16], some researchers believe that corticoster-
oid injections may even delay the natural recovery
expected with watchful waiting or other management
options [17], in addition to the high rate of symptoms
recurrence noted with its use.
With recent histological ﬁndings showing that
tendinosis is not an acute inﬂammatory condition but
rather a failure of normal tendon repair [18,19]
researchers started to focus on the function of biologics
in treating LE [20], including Platelet-rich Plasma (PRP)
injection [21]. Firstly introduced by Whitman, Berry, &
Green [22], PRP has a 3–5 fold increase of platelet
concentration compared to whole blood levels [23], and
includes many growth factors essential for bone-to-tendon
healing, aswell as other vascular, epidermal and connective
tissue growth factors [24]. Different laboratory studies
showedenhanced tenocyteproliferationafter injectionwith
platelet-released growth factors [25,26]. However, andwith
the insufﬁcient evidence available to support its clinical use
[27], PRP injections continues to be debated in the
literature, especially with the lack of its comparable rapid
therapeutic effect compared to other pharmacological
treatments [28,29].
Although a number of randomised controlled trials
compared the effect of corticosteroid and PRP injection
for treating LE, an up-to-date systematic review of these
primary studies is lacking within the literature. While
some reviews [17,30] assessed the effect of various injection
therapies for LE, none of these studies investigated the
effect of PRP injection as a comparative therapy for the
treatment of LE.On the other hand, andwhile a number of
systematic reviews [31–33] focused on the effect of PRP
injections, none of these compared the outcome of this
injection therapy with other injection modalities, includ-
ing corticosteroid injections. Some reviews and meta-
analyses recently includedmore primary studies about the
effect of PRP and steroid injections [34–36], but again,
none of these reviews focused or speciﬁcally compared the
effect of steroid and PRP injection therapies. This
attributed to the fact that these reviews were aiming at
collectively comparing the effects of different injection
therapies to obtain a general conclusion about their effect
in LE. As a result, this has hindered for a conclusion to be
drawn about the effects peculiar to steroid and PRPinjections, leaving a gap in the literature, with inadequate
knowledge available to inform the relevant clinical
practices. In this systematic review, we aim to systemati-
cally accumulate the evidence available from the relevant
primary studies about the effect of these two treatments.
We hypothesise that PRP injection provides longer-term
therapeutic effect and less rate of complications compared
to corticosteroid injection.
Methodology
Study selection criteria Although the main focus
was on RCTs, all interventional studies were eligible for
inclusion in this study. The search strategy of this review
was structured using Population, Intervention, Compari-
son, Outcome framework (PICO). Free-text searching and
Medical Subject Headings were also considered.
Search strategy The search strategy was conducted
and reported in accordance with PRISMA guidelines [37]
and Cochrane Collaboration [38] whenever possible. It
also adhered to the published guidance used when
undertaking reviews in healthcare [39]. Eleven databases
were systematically searched, namely, Web of science,
Scopus, PubMed (MedLine), ScienceDirect, CINAHL,
EMBASE, Ovid, NICE, Physiotherapy Evidence Data-
base, Cochrane Library and ClinicalTrials database
(Figure 1). As we aimed to search for only the recent
and relevant evidence, only papers published from 2005
onwards were accessed, and hand-searched for their
bibliographic references to look for any relevant refer-
ences. The search was also enhanced using forward
citation searching strategy, with searching by author and
study title was also considered using Web of Science
Service. Cochrane Database of Systematic Reviews,
Cochrane Central Register of Controlled Trials, and
database of abstracts of reviews of effectiveness were also
consulted. Potentially relevant studies, which are
labelled as ongoing studies, were searched for using
International Clinical Trials Registry Platform, UK
Clinical Research Network Study Portfolio, US National
Library of Medicine Database of Clinical Trials and
metaRegister of Controlled Trials. Database bias was
eliminated as possible, by reviewing journals which were
not indexed in major bibliographic databases. Finally,
potentially relevant studies in the grey literature was also
considered to identify any unpublished research or
research produced outside the traditional distribution
channels.
Only Papers published in English language were
included in this review, although it was aimed initially
to consider papers written in non-English languages too,
including two papers in Turkish language. Nevertheless,
and as the accuracy of quality assessment and data
extraction could be affected when translating non-English
papers, it was ﬁnally decided to restrict the work on papers
written in English language. This was also supported by
the evidence that language restriction does not appear to
change the results of systematic reviews conducted on
RCTs of conventional interventions [40].
7 study papers 
considered 
 732 potentially relevant study papers identified by search strategy: 
 199 (Web of science) 
  84 (PubMed: Including MEDLINE) 
 109 (Scopus) 
 340 (Other databases - refer to the methodology section) 
689 articles were excluded because 
of the following reasons: 
- Duplicate papers. 
- Review articles. 
- Conference papers,           
periodicals, editorials, etc. 
43 papers selected 
36 study papers were excluded 
(after reading the papers abstracts) 
because of the following reasons: 
- Protocol-only study papers 
- No comparative assessment of 
interventions 
- Comparison of irrelevant 
treatment interventions 
2 study papers written 
in non-English 
language (Turkish) 
5 primary studies included 
in this systematic review 
Figure 1. PRISMA Flow Chart showing the studies’ selection process which led to the inclusion of the ﬁve study.
W. Ben-Nafa and W. Munro: SICOT-J 2018, 4, 11 3Some of the experts in the ﬁeld pertinent to this review,
including some of the included studies’ authors, were
contacted to inquire about any ongoing or unpublished
relevant studies. No relevant studies were declared by the
authors.
The process of inclusion of relevant studies was
independently conducted by the two authors, and consen-
sus has been reached between the two reviewers with no
need for a third opinion. Exclusion criteria included old
studies conducted before 2005, study population with
elbow pain/pathologies other than LE, and injection
materials other than corticosteroid or PRP, including
autologus blood and autologous conditioned plasma
injections, which were excluded due to their irrelevancy.
The data extraction process was performed before
assessing the quality of the studies, to enhance the
objectivity in collecting data regardless of the quality.
The process of data extraction was carried out indepen-
dently by the two reviewers as well. A pilot data
extraction form [41] was created and tested by the tworeviewers before embarking on the data extraction
process, to test the comprehensiveness and objectivity
of the extraction form.
To objectively illustrate all the potential biases of the
studies in a comparative style, a table has been compiled
to evaluate the included studies against different
checklist elements used to assess potential biases in
RCTs [41–44]. The reviewers independently appraise
and eventually agreed on the quality of the included
studies (Table 1).
Results
Eleven electronic databases were searched up to
February 2017 without language, publication, or study-
designs restrictions (Figure 1). Out of 732 papers identiﬁed
in the body of literature, 43 study papers were considered
after excluding duplicate papers, review articles, confer-
ence papers and other irrelevant articles. Five studies
[29,45–48], including 250 patients, were ﬁnally considered
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he
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r p
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aƟ
on
. 
an
y 
re
-
in
te
rv
en
Ɵo
ns
 o
r 
ot
he
r t
re
at
m
en
ts
 
gi
ve
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en
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18
 p
ar
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an
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iv
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re
-in
te
rv
en
Ɵo
ns
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- I
nt
er
ve
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on
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ro
up
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 o
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Ɵo
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on
 C
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 C
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 C
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 C
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 C
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 re
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 re
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 p
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Table 4. Details of steroid and PRP preparations used by the included studies.
Steroid preparaƟons 
Study Type of corƟcosteroid 
used 
Dose and 
concentraƟon 
Type, dose & concentraƟon of 
local anaestheƟc used 
Peerbooms et al. 
(2010) 
Triamcinolone 
acetonide 
1 ml (40 mg/ml) Bupivacaine hydrochloride 0.5%     
+  Epinephrine (1:200000) 
Gosens et al. 
(2011) 
Triamcinolone 
acetonide 
1 ml (40 mg/ml) Bupivacaine hydrochloride 0.5%     
+ Epinephrine (1:200000) 
Krogh et al. (2013) Triamcinolone 1 ml (40 mg/ml) 2 ml  lidocaine 10 mg/mL 
Gautam et al. 
(2015) 
Methylprednisolone 2 ml (40mg/ml) NIG (1) 
Omar et al. (2012) NIG NIG NIG 
PRP preparaƟons 
Study volume Platelets 
concentraƟon 
(compared to platelets 
concentraƟon in blood) 
DuraƟon 
between blood 
collecƟon and 
PRP injecƟon 
Exogenous 
platelets 
acƟvaƟon 
Buﬀering agent 
Peerbooms 
et al. 
(2010) 
3 ml NIG Around 30 
minutes 
No 8.4% sodium 
bicarbonate + 
bupivacaine 
hydrochloride 0.5%   
+ epinephrine 
(1:200000) 
Gosens et 
al. (2011) 
3 ml NIG Around 30 
minutes 
No As above 
Krogh et 
al. (2013) 
3- 3.5 
ml 
8 folds Injected directly 
aŌer preparaƟon 
NIG 8.4% sodium 
bicarbonate 
Gautam et 
al. (2015) 
2 ml NIG NIG NIG NIG 
Omar et al. 
(2012) 
NIG At least 2 folds NIG NIG NIG 
(1) NIG: No information given
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The quality appraisal of the included studies is summar-
ised in Table 1. In addition, Studies’ characteristics,
demographic details and details of treatment preparations
have also been listed (Tables 2–4).
Analytic data of the included studies With
careful observation of the studies’ outcome results
(Tables 5–7), it can be concluded that there was a
general trend by most of the studies showing that PRPhas slower but longer-term clinical effect with no
recurrence of symptoms over the follow-up periods
included. This was almost the opposite with the use of
corticosteroid injections.
Safety of interventional materials used Besides
some of the known local adverse effect [49,50], no other
complications or systematic effects were reported
(Table 8). Except for one study [29], The lack of details
regarding the rate/number of complications incidence
Table 5. Values for Visual analogue scale (VAS) & Disabilities of the Arm, Shoulder and Hand (DASH) as reported by the included
studies. (1) SD: Standard deviation; (2) CS: Corticosteroid; (3) PRP: Platelet-rich plasma. (P: P value).
Visual analogue scale (VAS)  
         Follow-up intervals 
 
       
study name & 
intervenƟons used 
 
Baseline 
Value 
±SD(1) 
 
2 Weeks 
 
 
1 month 
(4weeks) 
 
 
6 weeks 
 
 
8 weeks 
 
 
3 months 
(12 
weeks) 
 
 
6 months 
(26 
Weeks) 
 
 
52 weeks 
 
 
104 
weeks 
 
 
Scale 
used 
Peerbooms   
et al. (2010) 
CS(2) 65.8 ±13.8  44.2 ±26.4  42.9 ±29.2 44.2 ±27.1 56.6 ±23.2 50.1 ±28.1  (0 - 100) 
PRP(3) 70.1 ±15.1  55.4 ±24.2  46.9 ±24.9 38.7 ±27.2 32.6 ±31.5 25.3 ±31.2  
Gosen et al. 
(2011) 
(Data 
according to 
intenƟon-to-
treat 
analyses) 
CS 66.2 
± 
14.0 
( P
:  
0.
34
0 )
 
 44.3 
± 
26.3 
( P
: 0
.0
23
)  
 43.4 
± 
28.9 
( P
: 0
.4
11
) 
45.5 
± 
27.1 
( P
: 0
.3
19
) 
55.8 
± 
24.1 
( P
: <
 0
.0
01
)  
48.8 
±27.0 
( P
: <
 0
.0
01
) 
42.4 
±26.8 
( P
: <
 0
.0
01
) 
(0 - 100) 
PRP 69.0 
± 
15.9 
 55.7 
± 
24.1 
 47.7 
± 
25.0 
40.2 
± 
27.5 
32.9 
± 
30.8 
25.9     
± 
30.6 
21.3 
±28.1 
Krogh et al. 
(2013) 
CS N o t  a p p l i c a b l e 
PRP 
Gautam et al. 
(2015) 
 
CS 
7.0 
±0.8 
(P
: 0
.6
50
) 
2.1 
±0.7 
(P
: 0
.0
00
) 
 1.4 
±0.5 
(P
: 0
.0
00
) 
 1.7 
±0.5 
(P
: 0
.4
93
) 
2.9 
±1.2 
(P
: 0
.0
01
) 
  (0 - 10) 
PRP 7.1 
±0.8 
4.5 
±1.1 
 2.7 
±0.8 
 1.8 
±0.6 
1.6 
±0.5 
  
Omar et al. 
(2012) 
CS  
8.6 ±1.6 
   
4.3 ±2.1 
(P:<0.001) 
     (0 - 10) 
PRP  
8.0 ±1.4 
   
3.8 ±1.9 
(P:<0.001) 
     
DisabiliƟes of the Arm, Shoulder, and Hand QuesƟonnaire (DASH)  
       Follow-up Intervals  
Study  
name and                               
interventions used 
 
Baseline 
±SD 
 
2 
Weeks 
 
1 month 
(4 
weeks) 
 
6 weeks 
 
 
 
8 weeks 
 
3 months 
(12 
weeks) 
 
6 months 
(26 
Weeks) 
 
52 weeks 
 
104 
weeks 
Peerbooms      
et al. (2010) 
CS  131.2 ± 
58.2 
 97.4 ± 69.0  84.7 ± 73.4 92.2 ± 68.7 117.3 ± 75.6 108.4 ± 82.2  
PRP  161.3 ± 
62.4 
 135.9 ± 
78.0 
 113.4 ± 79.6 92.0 ± 78.8 79.5 ± 80.3 54.7 ± 73.2  
Gosen et al. 
(2011) 
(Data according 
to intenƟon-to-
treat analysis) 
CS  43.3 
± 16.1 
   
 ( 
P:
 0
.0
02
) 
 31.2 
± 
20.8 
   
  (
 P
: 0
.0
05
) 
 28.3 ± 
22.2 
   
   
  (
P:
 0
.0
60
) 
32.3 ± 
21.7 
   
   
  (
P:
 0
.8
13
) 
37.6 ± 
23.1 
   
   
  (
P:
 0
.0
37
) 
36.8 
± 
24.0 
   
  (
P:
 <
 0
.0
01
) 
36.5 ± 
23.8 
   
  (
P:
 <
 0
.0
01
) 
PRP 54.3 ± 
19.5 
 43.1 
± 
21.6 
 37.2 ± 
24.7 
21.3 ± 
22.0 
27.8 ± 
24.7 
20.0 
± 
23.5 
17.6 ± 
24.0 
Krogh et al. 
(2013) 
CS          
PRP          
Gautam et al. 
(2015) 
 
CS 
67.5 
±6.9 
   
   
  (
 P
: 0
.3
78
)  39.7 
±6.7 
   
   
   
(P
: 0
.0
00
)  32.7 
±4.1 
   
   
  (
P :
 0
.0
03
)  34.3 
±3.3 
   
   
   
(P
: 0
.6
75
) 39.6 
±1.0 
 (P
: 0
.0
12
) 
  
PRP  
69.7 
±6.1 
 
51.6 
±6.8 
 38.6 
±5.7 
 33.6 
±5.1 
32.0 
±4.5 
  
Omar et al. 
(2012) 
CS  
57.3 ±10.3 
  20.2        
±14.0 
(P<0.001) 
     
PRP  
58.9 ±10.5 
 
  19.9 
±12.9 
(P<0.001) 
     
(1) SE: Standard error. (2) CS: Corticosteroid. (3) PRP: Platelet-rich plasma.
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Table 6. Outcome values for Patient-Rated Tennis ElbowEvaluation (PRTEE), Oxford elbow score,ModiﬁedMayo score andHand
grip strength at different follow-up intervals.
 
Outcome measure used 
  
Patient-Rated Tennis Elbow Evaluation (PRTEE)    Krogh et al. (2013) 
 
Follow-up intervals 
 
Baseline 1 month 3 months 
 
Outcome measure 
elements 
(Mean Pain 
score: 0-50) 
& SE (1) 
(Mean 
FuncƟonal 
score: 0-
100) 
& SE 
(Mean 
Change in 
Pain) 
& SE 
(Mean 
Change in 
Disability) 
& SE 
(Mean 
Change in 
Pain) 
& SE 
(Mean Change 
in in Disability) 
& SE 
 
 
Interventions  
 
CS (2) (28.0) 8.0 (51.1) 22.3 (- 9.8) 
2.2 
(- 21.9) 
4.3 
(- 7.1) 
2.2 
(- 13.8) 
4.3 
PRP (3) (27.5) 7.5 (51.5) 19.1 (- 0.5) 
2.2 
(- 5.2) 
4.3 
(- 6.0) 
2.2 
(- 16.6) 
4.3 
Saline (25.0) 7.3 (47.1) 22.3 (- 1.7) 
2.2 
(- 3.4) 
4.3 
(- 3.3) 
2.2 
(- 7.6) 
4.3 
 
Outcome measure used 
 
Oxford Elbow Score (Value) ±SD (4)     Gautam et al. (2015) 
 
Follow-up intervals 
 
 
Baseline 
 
2 weeks 
 
6 weeks 
 
3 months 
 
6 months 
 
Interventions  
 
CS 
 
(31.2) ±4.1 
(P
: 0
.0
15
) 
 
(39.7) ±3.4 
(P
: 0
.0
01
) 
 
(41.5) ±2.5 
(P
: 0
.0
45
) 
 
 
(41.7) ±2.4 
(P
: 0
.0
29
) 
 
(36.3) 
±5.9 
(P
: 0
.0
07
) 
 
PRP 
 
(27.4) ±3.9 
 
(34.7) ±4.3 
 
(39.3) ±3.1 
 
(39.3) ±3.3 
 
(41.2) 
±2.7 
 
Outcome measure used 
 
Modified Mayo Score (Value) ±SD     Gautam et al. (2015) 
 
 
Follow-up intervals 
 
 
Baseline 
 
 
2 weeks 
 
6 weeks 
 
 
3 months 
 
6 months 
 
Interventions  
 
 
CS 
 
(56.8) ±5.4 
 
( P
: 0
.7
70
)  
 
(68.5) ±3.9 
(P
: 0
.0
00
) 
 
(70.4) ±3.2 
( P
: 0
.0
17
) 
 
(69.6) ±3.5 
( P
: 0
.5
78
)  
 
(61.5) 
±5.8 
(P
: 0
.0
00
) 
 
PRP 
 
(56.1) ±6.9 
 
 
(61.3) ±3.1 
 
(67.7) ±2.6 
 
(70.2) ±2.2 
 
(70.7) 
±3.0 
 
Outcome measure used 
 
Hand grip strength (Value) ±SD     Gautam et al. (2015) 
 
 
Follow-up intervals 
 
 
Baseline 
 
2 weeks 
 
6 weeks 
 
3 months 
 
6 months 
 
Interventions  
CS  (19.2) ±4.6 
 
(P
: 0
.6
83
) 
 
(25.5) ±4.9 
( P
: 0
.1
59
)  
 
(25.5) ±6.0 
( P
: 0
.9
76
)  
 
(25.8) ±6.7 
( P
: 0
.8
84
)  
 
 
(23.3) 
±6.5 
( P
: 0
.2
58
)  
 
PRP 
(18.5) ±5.1 
 
 
(22.5) ±6.6 
 
(25.5) ±6.3 
(25.5) ±5.6  
(25.9) 
±6.2 
(1) SE: Standard error. (2) CS: Corticosteroid. (3) PRP: Platelet-rich plasma. (4) SD: Standard deviation. (P:P value)
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Table 7. Ultrasonographic outcome data reported by 2 studies.
       Study name &         
         Interventions used    
The               
Outcome  
measures used                       
(at 3 different 
follow-up periods) 
Krogh et al. (2013) Gautam et al. (2015) 
Corticosteroid 
injections 
 
Platelet-
rich 
plasma 
Corticosteroid 
injections 
 
Total:15 Patients 
Platelet-rich 
plasma 
 
Total:15 Patients 
 
DA (1) 
(Mean Value) ±SD 
(α) 
 
0 (A) 
(3.2) ± 0.9 (3.8) ± 0.4   
         
 Δ DA (2)  
(Mean Value) SE (β)  
 
3 M (B) (- 3.0) 0.2 (- 0.4) 0.2   
 
6 M (C) 
    
 
             TT (3)  
(Mean Value) ±SD  
 
 
0 
(5.1) ± 0.8 (5.4) ± 0.6   
         
          Δ TT (4)  
(Mean Value) SE  
 
3 M (- 0.2) 0.1 (0.3) 0.1   
   6 M     
 
No. & (%) TCET 
(5) 
0   5 (33) 10 (67) 
3 M   4 (27) 8 (53) 
6 M   5 (33) 4 (27) 
 
No. & (%) OCET 
(6) 
0   7 (47) 7 (47) 
3 M   3 (20) 6 (40) 
6 M   2 (13) 1 (7) 
 
No. & (%) RTCET 
(7) 
0   2 (13) 3 (20) 
3 M   4 (27) 2 (13) 
6 M   12 (80) 1 (7) 
 
No. & (%) PIT(8) 
0   15 (100) 15 (100) 
3 M   9 (60) 10 (67) 
6 M   10 (67) 6 (40) 
 
No. & (%) CELE 
(9) 
0   9 (60) 14 (93) 
3 M   11 (73) 14 (93) 
6 M   11 (73) 14 (93) 
(1) DA: Doppler activity (Grades 0–4); (2) D DA: Change in Doppler activity; (3) TT: Thickness of common extensor tendon (in
millimetres); (4) D TT: Change in Thickness of common extensor tendon; (5) No. and (%) TCET: Number and percentage of patients
who had tears in the common extensor tendon; (6) No. and (%) OCET: Number and percentage of patients who had oedema in the
common extensor tendon; (7) No. and (%) RTCET: Number and percentage of patients who had reduced thickness of the common
extensor tendon; (8) No. and (%) PIT: Number and percentage of patients who had probe-induced tenderness; (9) No. and (%) CELE:
Cortical erosion at the lateral epicondyle. (a) SD: Standard deviation; (b) SE: Standard error. (A) 0: baseline assessment; (B) 3M: 3
month; (C) 6M: 6 months.
10 W. Ben-Nafa and W. Munro: SICOT-J 2018, 4, 11among the participants prevents any quantitative analysis
to assess the prevalence of these complications among
studies’ participants.
Discussion
Five primary studies were included in this systematic
review (Table 2). All these studies were high in the
hierarchy of evidence and followed the randomised
controlled trials (RCTs) design [51]. Two of these studies
[45,46] were merely a two-stage trial rather than two
distinctive studies. Initially, Peerbooms and colleagues
investigated the effect of corticosteroid versus PRP
injections, with an end-point assessment at 1 year, which
was followed by an assessment of the longer-term effect ofthe two interventions at 2 years, by Gosens and co-
researchers. However, and as the two studies were not
conducted by exactly the same researchers, and with two
distinctive articles with study titles, it appears that the
authors in the ﬁrst study did not originally plan to
measure the patient’s outcomes at 2 years. This have
entailed some changes in the studies settings, including
the use of two different variants of one of the main
outcome measures used (DASH). This was declared by
one of the authors who stated that all DASH items were
summed in the ﬁrst study, yet the core elements only
were used to calculate the DASH score in the second
study. Secondly, the two studies were conducted at two
teaching hospitals, with no details about which patients
Table 8. Adverse effects of injection therapies as reported by the review studies.
Study Adverse effects 
Peerbooms et al. (2011) Local inflammation at the injection site, which caused 
increased pain 3 to 4 weeks after the injection 
Gosens et al. (2011) Initial worsening of localised pain (1 - 2 weeks). 
 
Krogh et al. (2013) 
Generic 
adverse 
effects 
PRP Corticosteroid 
 
post 
injection 
pain 
 
- persistent pain       
(4 subjects) 
- Reduced elbow 
movement (3 
subjects) 
- localised skin rash 
(1 subject) 
- local skin atrophy 
(3 subjects) 
- loss of skin 
pigmentation (1 
subject) 
- Persistent pain (1 
subject) 
Gautam et al. (2015) NIG 
Omar et al. (2012) NIG 
(NIG: No information given)
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hospital settings were similar, and thus more details
could have eliminated any potential bias.
While consecutive sampling was adopted by two
studies [45,46], no details provided by the other studies
[29,47,48]. Population’s details, which are important to
assess the external validity, varied widely among the
included studies (Table 3). Age and gender ratios of
participants were generally representative of the popu-
lation, although no demographic data were provided by
one study [47]. Also, and while Krogh and co-researchers
(2013) [29] provided the most extensive details of
patient’s demographic data including smoking history,
the percentage of patients who were current smokers
varied widely among the three study arms, which ranged
between 10 % in saline group, to around one-third in
PRP and glucocorticoid groups. With the known
correlation between smoking and delayed tissue healing[52,53], the variation in this demographic element
(smoking) can be considered as a confounding factor
especially if we observe the comparable therapeutic
effect noted in saline (placebo) group compared to
corticosteroid and PRP groups.
The randomisation process and allocation of study
population was not reported by two studies [47,48], which
entails a potentiality of selection bias, and questions the
quality of these two high-level evidence RCTs. Addition-
ally, the lack of blinding of outcome assessors was one of
the main limitations faced by most of the included studies.
Krogh and co-researchers [29] were the best who reported
these elements. Peerbooms and co-researchers [45] only
reported the blinding of patients to treatment interven-
tions, Gautam and colleagues [47] only reported the
blinding of ultrasound operator(s), while the study by
Omar and co-researchers [48] lacked the information
about all the elements of the blinding process.
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ing the trials is another important element. Althoughmost
studies reported that patients received no treatments in
the last 3–6months before the interventions, there is still a
potential long-term effect of any treatments given before
that, this in addition to the possible treatment-treatment
interactions after receiving the new interventional treat-
ments. This might be of real signiﬁcance if we noted, for
instance, that steroid injection was received by as high as
58 % of patients received corticosteroid injections in the
trial by Krogh and co-researchers [29]. Additionally, and
with the considerable variation of the disease duration
before the treatment interventions, it is unclear how far
this kind of heterogeneity has a role when assessing the
comparative effect of the treatments given.
Injection materials used While the use of cortico-
steroid as a control injection can be acceptable to compare
the effect of PRP, the use of such medicinal therapeutic
agent itself may undermine the accurate assessment of the
effect of PRP as a treatment option. For example, the
probable deleterious effects of corticosteroid [17] may
falsely exaggerate the beneﬁcial effect of PRP in
comparison. Additionally, and although Krogh and co-
researchers avoided this potentially confounding element
by using saline as a placebo injection, the saline material
itself could be considered more than an inactive compara-
tor substance, with its possible beneﬁcial/harmful effects
as well.
The use of different types, doses and concentrations of
the interventional steroid preparations (Table 4) should
be noted, especially with the known difference of the
therapeutic effect of these preparations [55,56]. Addi-
tionally, the combined use of local anaesthetics with
steroid preparations in some studies [29,45] can be a
source of bias as well, as these anaesthetic agents add
volume to the injectate and help distributing the
corticosteroid substance within the affected tissues
[57], with possible changes in the effect of corticosteroid
injections. This kind of heterogeneity can be seen more
profoundly with the use of PRP injections, where
different preparation methods, various commercial
centrifugation/separation systems as well as different
concentrations of platelets, growth factors and other
blood products in the PRP preparations were used [58–
63] (Table 4). With no ideal concentrations of platelets
and growth factors in the PRP preparations has been
established yet, these sources of variability were clearly
observed in the included studies. This in addition to
technical details including centrifugation speed, buffer-
ing agents used to achieve physiological pH, and the time
needed for the centrifugation of blood.
Although all of the included studies used one-phase of
treatment delivery of one injection, different injection
sites, techniques and methods were used.While peppering
technique (multiple tendon perforations) was adopted by
two studies [45,47], Krogh and colleagues used 1 direct
injection for corticosteroid while adopted peppering
technique for PRP and saline injections [29], which couldhave resulted in more pain in the early follow-ups
compared to those who received single-injection cortico-
steroid. This difference in injection technique may have
distributed the injectates differently in the study arms,
with possible subsequent different therapeutic effects in
vivo. Additionally, the same study [29] adopted the
practice of injecting local anaesthetic in the peritendon
(the connective tissue sheath around the tendon) before
administering the interventional treatments, with possible
subsequent detrimental effects on tendon cells viability
and thus change in treatment effect [64]. Also, the possible
mix of lidocaine with PRP at nearly the same site, could
have reduced the therapeutic effect of PRP, as it is shown
that local anaesthetics reduce the positive effects of PRP
[65]. It is unclear how much these details could have
affected the treatment delivery and subsequently the
therapeutic effect of the used treatments. Finally, and
with the inter-personal bias in mind, Peerbooms and co-
researchers [45] reported that treatments were given by
more than one person of different level of experience
(consultant and resident doctors), whichmight entail that
treatments could have been given differently. This
confounding factor has not been ruled out by two of
included studies [47,48].
Regarding the cost-effectiveness of the injection
treatments used, PRP injections may not be of interest
to healthcare providers with an overall cost of around ($
840–1000), compared to approximately one-third of this
for corticosteroid injections [45,54]. However, the higher
rate of symptoms recurrence among the relatively cheap
corticosteroid injections means that the expenses of new
treatments, including the higher costs of surgical treat-
ments for example [54], which might be required after
these cheap modalities fail, may entail higher cost than a
single PRP injection.
In all of the included studies, the participants were
provided with some forms of post-injection therapies,
including different physiotherapeutic modalities
[29,45,46]. It should be noted here that these modalities
are known for their therapeutic effect in lateral epicondyl-
opathy [66,67], and again this might have created a source
of uncertainty when assessing the real effect of the injected
treatments.
Outcome measures used by the review studies
It is clearly seen the degree of heterogeneity when
observing the various outcome measures used by the
included studies (Table 5). When assessing the outcome
measures used by the ﬁrst two studies [45,46], and while
there were minimal variations in the baseline VAS values
between corticosteroid and PRP study arms, signiﬁcant
differences in the DASH baseline scores were noted
(Table 5). This disparity necessitates careful interpreta-
tion of the DASH outcome results by the two studies.
While PRTEE has sufﬁcient psychometric properties
[68,69], it may lack the objectivity and thus the accurate
assessment, as it depends solely on the subjective
patient-rated evaluation, beside the fact that this was
the only clinical outcome measure used by Krogh and
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difﬁculty in comparing the clinical outcomes of this trial
[29] with the other 4 studies which used VAS and DASH
in their outcome measurement.
Drop-out of participants Variable drop-out rates
were reported by the included studies. While (6%)
reported by Gosens and colleague [46] by the end of their
trials at 102 weeks, Krogh and colleagues [29] reported a
0% of drop-out at 3months. However, considering the high
drop-out which faced Krogh and colleagues at 12 months
(around 73%), it can be argued here that this could be the
main reason for these researchers to limit the study follow-
up to 3-month only. Interestingly, and with careful
observation of this study, it can be seen that the drop-
out rate among patients who received PRP was signiﬁ-
cantly less than that in corticosteroid group beyond the 6-
month period. This could have been caused by the late
ongoing therapeutic effect of PRP, which might have
encouraged the patients to adhere to their original
interventional treatment option (PRP).
Finally, and with the above reported data in mind, a
few ﬁnal observations should be elaborated here. Firstly,
although most of the included studies followed the trend
of rapid reduction then a regaining increase in the VAS
and DASH values for the use of corticosteroid, there was a
unique trend observed at 52 weeks and 104 weeks by the
two consecutive studies [45,46]. This trend shows that the
VAS andDASH values in the corticosteroid group started
to fall again, which means that there were improvements
in pain and function at these two follow-ups. Although
this might be interpreted as an ongoing long-term
improvement using corticosteroid, it should be remem-
bered that this could have resulted from the fact that 13
out of 20 patients on the corticosteroid group have
received further treatments (re-intervention) after the
original treatments. Secondly, Krogh and co-researchers
[29] reported that no superior outcomes can be observed
with the use of PRP compared to saline and corticosteroid
injections. This can be attributed to the fact that the
study did not assess the longer term effects of PRPbeyond
3 months, which could have shown improvement in the
PRP group compared to corticosteroids group, especially
that more clinical improvement started to appear in the
PRP group in the period between the 1- and 3-month
follow-ups. Additionally, the selective reporting by the
same researchers [29] is difﬁcult to be excluded here,
especially that the researchers who clearly reported the
higher clinical improvement in corticosteroid groups in
the period up to 1-month follow-up, did not similarly
acknowledge that this trend has reversed in favour of PRP
in the subsequent follow-up. Thirdly, despite the
comparatively longer-term therapeutic effects of PRP,
the self-limited nature of LE should always be remem-
bered, as this might have a role in the condition
improvement on the mid- to long-term [70], although
this effect was not observed in the corticosteroid groups
who experienced deterioration in their symptoms on the
mid- to long-term. Fourthly, the short-term therapeutic
effect and high rate of symptoms recurrence followingcorticosteroid injections could be attributed to the fact
that these patients usually experience relatively rapid
improvement of symptoms which encourage them to rely
on the affected limb prematurely, with the possible re-
injury of the newly treated tendon and subsequently a
recurrence of symptoms [29,46]. The role of this factor
can be investigated in the future, by observing the
participant’s return to daily activities and assessing/
restricting their degree of reliance on the affected limb
after receiving the treatment. Finally, and despite the
strong argument which states that LE is a degenerative
non-inﬂammatory process, the rapid therapeutic effect
provided by corticosteroid injections needs to be justiﬁed
here, which could hypothesise that the disease itself
could be caused by a combined pathophysiological
mechanisms, which could involve both inﬂammatory
and degenerative processes.
Limitations of this review The relatively small
number of included studies, the ambiguity of some studies’
methodological details, and the potential biases noted in
many of the trial’s aspects are the main limitations of this
review. Additionally, and while the quantitative analysis
(meta-analysis) was considered in this review, the varied
outcomemeasures used and the different timings of follow-
ups have hindered the chance to conduct a meta-analysis
to draw a large-scale summative conclusion.
Recommendations for future research With the
wide variation in using the injection treatments, there is a
growing need to carefully assess and compare many of
these treatments settings, aiming to adopt a uniﬁed
preparation/technique, especially with PRP injections,
where different separation systems, concentrations of
blood components and injection techniques are used. For
example, with the different injection methods used by
various studies, the adoption a computer-guided injection
technique [54] can be utilised to enhance needle placement
and to avoid potential variability during the injection
process. It can be also suggested that a uniﬁed injection
protocol can possibly be used to standardise the mode of
injection, including for instance, the speciﬁc use of
peppering or single-dose injection, agreeing on a pre-
determined injection site, deﬁning speciﬁc numbers of
injections, and to determine whether local injections will
be used before/with corticosteroid and PRP injection.
Furthermore, the use of post-injection therapeutic modal-
ities should be regulated, by possibly avoiding or at least
adopting a uniﬁed post-injection protocol. That also
applies to the outcome measures used, as this can
considerably help comparing the clinical outcomes more
efﬁciently. These variables, if considered, can eliminate
any potential variations and thus help towards unbiased
assessment of the effect of the injection treatments.
Finally, it should be noted here that none of the included
studies reported any details about the ethnicity of the
studies’ population, where different ethnic groups might
have different response to different treatments. Investi-
gating this variable in the future could reveal further
information about the disease pathophysiology and its
management.
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Platelet-rich plasma demonstrated better, although
delayed, therapeutic effects compared to corticosteroid
injections, with no subsequent regression of their positive
clinical ﬁndings for up to 2 years, and with no reported
adverse effects except for local discomfort felt at the
injection site, as report by a single study. This conclusion
can be also supported by the fact that no long gaps can be
observed between the follow-ups conducted by all of the
included studies, and thus minimal chance of missed data,
whichmight demonstrate different change in effect, can be
assumed.
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